We are testing a new treatment, NS-229, to see if it helps patients with Eosinophilic Granulomatosis With Polyangiitis achieve remission better than a placebo. The study will also look at any side effects and the time until symptoms worsen.
Health conditions and diseases that the clinical trial is designed to study and treat.
Eosinophilic Granulomatosis with Polyangiitis (EGPA) is a rare autoimmune disease that causes inflammation of blood vessels, leading to symptoms such as asthma, sinusitis, and skin rashes. It primarily affects the lungs, skin, and nerves.
These questions help us understand your situation so we can let the trial team know whether you might be a potential match. This is not a medical evaluation and is not part of the official screening, the study doctor will make the final decision..
Experimental substances that are being investigated in this clinical trial. These are not yet approved for general use.
Locations and medical facilities where this clinical trial is currently recruiting or conducting research. Select the locations where you would like to participate.
Disclaimer: Parts of this content have been automatically extracted from the EU Clinical Trials registry. While we strive for accuracy, please always contact the trial site or sponsor directly for correct and official information before making any decisions about participation. View on EU Clinical Trials.
